-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Comparing Erasca (NASDAQ:ERAS) and Longboard Pharmaceuticals (NASDAQ:LBPH)
Comparing Erasca (NASDAQ:ERAS) and Longboard Pharmaceuticals (NASDAQ:LBPH)
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) and Erasca (NASDAQ:ERAS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.
Valuation & Earnings
This table compares Longboard Pharmaceuticals and Erasca's top-line revenue, earnings per share (EPS) and valuation.
Get Longboard Pharmaceuticals alerts:Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longboard Pharmaceuticals | N/A | N/A | -$27.80 million | ($2.43) | -2.35 |
Erasca | N/A | N/A | -$122.76 million | ($1.16) | -3.34 |
Erasca is trading at a lower price-to-earnings ratio than Longboard Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Longboard Pharmaceuticals and Erasca's net margins, return on equity and return on assets.Net Margins | Return on Equity | Return on Assets | |
Longboard Pharmaceuticals | N/A | -46.99% | -43.46% |
Erasca | N/A | -33.63% | -29.55% |
Institutional & Insider Ownership
53.5% of Longboard Pharmaceuticals shares are held by institutional investors. Comparatively, 65.8% of Erasca shares are held by institutional investors. 6.8% of Longboard Pharmaceuticals shares are held by company insiders. Comparatively, 37.5% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Longboard Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Longboard Pharmaceuticals and Erasca, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longboard Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
Erasca | 0 | 0 | 0 | 0 | N/A |
Longboard Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 163.16%. Given Longboard Pharmaceuticals' higher possible upside, research analysts plainly believe Longboard Pharmaceuticals is more favorable than Erasca.
Summary
Erasca beats Longboard Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Longboard Pharmaceuticals
(Get Rating)
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
About Erasca
(Get Rating)
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating) and Erasca (NASDAQ:ERAS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.
长板制药(纳斯达克:LBPH-GET Rating)和艾拉斯卡(纳斯达克:ERAS-GET Rating)都是小盘医疗公司,但哪只股票更好?我们将根据这两家公司的盈利能力、风险、收益、股息、分析师建议、机构所有权和估值等方面的实力进行比较。
Valuation & Earnings
估值与收益
This table compares Longboard Pharmaceuticals and Erasca's top-line revenue, earnings per share (EPS) and valuation.
该表格比较了长板制药和Erasca的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Longboard Pharmaceuticals | N/A | N/A | -$27.80 million | ($2.43) | -2.35 |
Erasca | N/A | N/A | -$122.76 million | ($1.16) | -3.34 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
长板制药 | 不适用 | 不适用 | -2,780万元 | ($2.43) | -2.35 |
埃拉斯卡 | 不适用 | 不适用 | -1.2276亿美元 | ($1.16) | -3.34 |
Erasca is trading at a lower price-to-earnings ratio than Longboard Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Erasca的市盈率低于Longboard PharmPharmticals,表明它目前是两只股票中更负担得起的一只。
Profitability
盈利能力
Net Margins | Return on Equity | Return on Assets | |
Longboard Pharmaceuticals | N/A | -46.99% | -43.46% |
Erasca | N/A | -33.63% | -29.55% |
净利润率 | 股本回报率 | 资产回报率 | |
长板制药 | 不适用 | -46.99% | -43.46% |
埃拉斯卡 | 不适用 | -33.63% | -29.55% |
Institutional & Insider Ownership
机构与内部人持股
53.5% of Longboard Pharmaceuticals shares are held by institutional investors. Comparatively, 65.8% of Erasca shares are held by institutional investors. 6.8% of Longboard Pharmaceuticals shares are held by company insiders. Comparatively, 37.5% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
长板医药53.5%的股份由机构投资者持有。相比之下,65.8%的Erasca股票由机构投资者持有。朗博制药6.8%的股份由公司内部人士持有。相比之下,Erasca 37.5%的股份由公司内部人士持有。强大的机构持股表明,对冲基金、捐赠基金和大型基金管理公司相信,一家公司的长期表现将好于大盘。
Volatility and Risk
波动性和风险
Longboard Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Long board PharmPharmticals的贝塔系数为1.02,这表明其股价的波动性比标准普尔500指数高2%。相比之下,Erasca的贝塔系数为1.28,这表明其股价的波动性比标准普尔500指数高28%。
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and target prices for Longboard Pharmaceuticals and Erasca, as provided by MarketBeat.com.
这是由MarketBeat.com提供的Longboard制药公司和Erasca最近的评级和目标价格细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Longboard Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
Erasca | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
长板制药 | 0 | 0 | 4 | 0 | 3.00 |
埃拉斯卡 | 0 | 0 | 0 | 0 | 不适用 |
Longboard Pharmaceuticals presently has a consensus price target of $15.00, suggesting a potential upside of 163.16%. Given Longboard Pharmaceuticals' higher possible upside, research analysts plainly believe Longboard Pharmaceuticals is more favorable than Erasca.
Long board PharmPharmticals目前的共识目标价为15美元,暗示潜在上涨163.16%。鉴于Longboard PharmPharmticals可能上涨的可能性更高,研究分析师明确认为,Longboard PharmPharmticals比Erasca更有利。
Summary
摘要
Erasca beats Longboard Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Erasca在两只股票比较的10个因素中有6个击败了Longboard PharmPharmticals。
About Longboard Pharmaceuticals
关于朗博德制药公司
(Get Rating)
(获取评级)
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
长板制药公司是一家临床阶段的生物制药公司,专注于开发治疗神经疾病的变革性药物。该公司的主要候选产品是LP352,它正处于1b/2a期临床试验,用于治疗与发育性和癫痫脑病相关的癫痫发作。它的临床前产品候选包括LP659和LP143,后者专注于开发多种神经疾病的治疗方法。该公司前身为Arena NeuroScience,Inc.,并于2020年10月更名为Longboard PharmPharmticals,Inc.Long board制药公司成立于2020年,总部设在加利福尼亚州拉荷亚。
About Erasca
关于伊拉斯卡
(Get Rating)
(获取评级)
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Erasca,Inc.是一家临床阶段的生物制药公司,专注于发现、开发和商业化RAS/MAPK途径驱动的癌症患者的治疗方法。该公司的主要候选药物包括ERK1/2口服抑制剂ERK1/2,用于治疗非小细胞肺癌、结直肠癌和急性髓系白血病;以及ERAS-601,一种用于晚期或转移性实体肿瘤患者的口服SHP2抑制剂。它还在开发ERAS-801,一种中枢神经系统穿透性EGFR抑制剂,用于治疗复发的多形性胶质母细胞瘤患者。该公司成立于2018年,总部位于加利福尼亚州圣地亚哥。
Receive News & Ratings for Longboard Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longboard Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《长板医药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Longboard制药公司和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧